
|Videos|August 3, 2017
Dr. Rosenberg on Immunotherapy in Non-Metastatic Muscle Invasive Bladder Cancer
Author(s)Jonathan E. Rosenberg, MD
Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses immunotherapy in patients with non-metastatic muscle invasive bladder cancer.
Advertisement
Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses immunotherapy in non-metastatic muscle-invasive bladder cancer.
Immunotherapy for this patient population is in an experimental stage, says Rosenberg.
Ongoing phase III trials are focusing on adjuvant therapy, which Rosenberg says patients who cannot receive platinum-based therapy after surgery should consider.
Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5




































